Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenamfetamine SCHEMBL9361151 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL29392330 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL30242630 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL30904507 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL15162053 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL30242515 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL30203543 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL30401290 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL5305879 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL22885190 | 0.89 | TAAR1 (0.81) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1698 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747639-A2 | BETA-GALACTOSIDASE ENZYME-BASED IMMUNOASSAY | Abbott Diagnostics Scarborough, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122076506-A | Composite catalyst for synthesizing berberine intermediate piperonylethylamine and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-4727538-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | claimed |
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| EP-4673125-A1 | R-MDMA FOR TREATMENT OF PAIN | Mind Medicine, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-12514883-B2 | Compositions and methods for modulating lipid and steroid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | claimed |
| EP-4662205-A1 | DERIVATIVES, IMMUNOGENS, AND ANTIBODIES AND USE OF THE SAME IN DETECTION OF ECSTASY-CLASS COMPOUNDS | Siemens Healthcare Diagnostics, Inc. (US) | 2025-12-17 | — | — | EP | claimed |
| US-12429484-B2 | Homogeneous enzyme immunoassay for keratinized structures | PSYCHEMEDICS CORPORATION (US) | 2025-09-30 | — | — | US | claimed |
| EP-4615828-A2 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EmpathBio, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20050130243-A1 | Assay for entactogens | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-06-16 | — | — | US | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004103283-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CENTRAL NERVOUS SYSTEM STIMULANT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | claimed |
| US-6669937-B2 | A monoclonal antibody that specifically recognizes a stimulant or hallucinogenic drug of abuse or a metabolite, selected from d-methamphetamine, d-amphetamine, 3,4-methylenedioxymethamphetamine or derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS | 2003-12-30 | — | — | US | claimed |
| US-20030119083-A1 | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-26 | — | — | US | claimed |
| WO-2003052426-A1 | A METHOD FOR THE DETECTION OF COMPOUNDS COMPRISING METHYLENEDIOXYPHENYL AND TESTING KIT FOR THE SAME | GLATTSTEIN ORA (IL) | 2003-06-26 | — | — | WO | claimed |
| US-20020013372-A1 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | claimed |
| US-20010051158-A1 | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | BIOVENTURES, LLC | 2001-12-13 | — | — | US | claimed |
| EP-1134290-A2 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | claimed |
| US-4120976-A | Treatments for arthritis and cast dermatitis | HOSICK THOMAS A | 1978-10-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | TAAR1 307/4885SLC6A4 2641/4885SLC6A2 2937/4885 |
| US-20050130243-A1 | Assay for entactogens | HTR3C, COMT, PNMT | TAAR1 336/4885SLC6A4 370/4885SLC6A2 966/4885 |
| US-20030119083-A1 | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | PNMT, EPHA5, EPHB1 | TAAR1 116/4885SLC6A4 449/4885SLC6A2 119/4885 |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | QPCT, SLC38A7, QPCTL | TAAR1 3179/4885SLC6A4 440/4885SLC6A2 362/4885 |
| US-20010051158-A1 | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | PNMT, EPHA5, EPHB1 | TAAR1 106/4885SLC6A4 441/4885SLC6A2 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.